ScripBack in March when it unveiled its full-year 2023, Merck KGaA made it clear that it was on the lookout for licensing deals. (Also see " Merck KGaA Wants Your Drugs " - Scrip, 7 March, 2024.) Today,
ScripIchnos Glenmark Innovation (IGI) believes its first-in-class T cell-engaging trispecific antibody has what it takes to make a mark in multiple myeloma (MM) , a segment dominated by big pharma players
ScripWho: Merck KGaA/Caris Life Sciences What: Caris’s research division will discover novel targets for use in cancer antibody-drug conjugate products to be developed by Germany’s Merck. Why: Merck K
Pink SheetThe US Food and Drug Administration’s Richard Pazdur does not come into an Oncologic Drugs Advisory Committee meeting with his mind made up on what regulatory action the agency is going to take on a c